Bioboost Synbio

What Bioboost Synbio does

Bioboost Synbio Inc. is a privately held Canadian synthetic biology company founded in late 2020 by Dr. Oleg Tyurin and Mingyang Sun, operating from Port Coquitlam, British Columbia with a team of 1-10 employees. The company's core asset is a proprietary methanol-free Pichia pastoris biosynthesis platform that eliminates the toxic, flammable, and explosive methanol feedstock traditionally required to drive Pichia fermentation, replacing it with a patented process that reduces fire hazards, lowers operational costs, and ensures zero toxic residue in the final product. The engineered platform, branded as Pichia 2.0, layers enhanced production capability, higher secretion rates (which compress downstream processing costs), and integrated chaperone proteins to handle complex protein folding on top of the methanol-free chassis.

Bioboost commercializes its technology through three channels: (1) direct e-commerce sale of Research Use Only recombinant proteins including Human Epidermal Growth Factor (hEGF) at $80 CAD per milligram, Recombinant Human Serum Albumin (rHSA) at $220 CAD per milligram, and Recombinant Brazzein protein sweetener at $220 CAD per 10 milligrams; (2) milestone-based research collaboration and co-development agreements, exemplified by an 18-month recombinant human lactoferrin project with Pinnacle Food Group AgTech HK Limited valued at approximately $580,000 CAD; and (3) technical consulting and ecosystem scouting across agtech, food tech, and biotechnology. Target customer segments include bioscience researchers (primary), cosmetics and skincare brands, functional food and beverage manufacturers, and pharmaceutical companies requiring high-purity recombinant proteins.

The company has secured granted patents in the United States (2022) and Canada (2023) on its methanol-elimination process, with applications pending in China and the European Union. It has built advisory relationships with former Merck Research Director Rina Carlini, former Willow Biosciences VP R&D Mathias Schuetz, and Harvard MBA Claire Dixon, and is integrated into eight Canadian biotech ecosystem organizations including Foresight Canada, Protein Industry Canada, and NRC-IRAP. As of 2026, Bioboost has five high-value proteins in its production pipeline and is commercializing its first molecules while pursuing geographic expansion into Greater China through an Open Yeast Platform initiative.

Name

Bioboost Synbio

Legal name

Bioboost Synbio Inc.

Website

https://bioboostsynbio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Bioboost Synbio is a Canadian synthetic biology company that operates a proprietary methanol-free Pichia pastoris fermentation platform to produce recombinant proteins for bioscience researchers, cosmetics brands, functional food manufacturers, and pharmaceutical companies, monetizing through RUO e-commerce sales, milestone-based co-development deals, and technical consulting.

Ownership category

akta.pro rank

Product category

Synthetic Biology Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

akta.pro secondary industries

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins) (AFAJAHAL), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Precision fermentation
• Recombinant proteins
• Yeast biosynthesis
• Synbio consulting
• Pichia pastoris platform

Headquarters

HQ city

Port Coquitlam

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Recombinant Protein Product Sales: Sale of recombinant proteins produced via the company's methanol-free Pichia biosynthesis platform. Products include Human Epidermal Growth Factor (hEGF), Recombinant Human Serum Albumin (rHSA), and Recombinant Brazzein (protein sweetener). Products are sold directly through the company website for research use only at fixed price points.
2. Research Collaboration Services: 18-month research and technology collaboration with Pinnacle Food Group AgTech HK Limited focused on recombinant human lactoferrin development and precision fermentation research. Milestone-based payments totaling approximately $580,000 CAD.
3. Consulting Services: Technical consulting, ecosystem scouting, and strategic evaluations across agtech, food tech, and biotechnology sectors. Advisory services for lab setup, regulatory compliance, and operations.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Bioboost Synbio operates a proprietary methanol-free Pichia pastoris precision fermentation platform that produces high-value recombinant proteins without the toxic methanol feedstock of conventional Pichia systems. The company sells three commercial Research Use Only (RUO) proteins — Human Epidermal Growth Factor (hEGF), Recombinant Human Serum Albumin (rHSA), and Recombinant Brazzein — through its e-commerce storefront for research applications, and delivers paid synthetic biology consulting, research collaborations, and technology development services to biotech, food, cosmetics, and pharma customers.

Product overview

Bioboost Synbio offers a proprietary methanol-free Pichia pastoris biosynthesis platform that enables sustainable precision fermentation for producing recombinant proteins. The portfolio includes three commercial Research Use Only (RUO) products: Human Epidermal Growth Factor (hEGF), Recombinant Human Serum Albumin (rHSA), and Recombinant Brazzein (protein sweetener). The platform technology comprises core components including Pichia 2.0 (enhanced host strain), Higher Secretion Capability, and Chaperone proteins. All products are yeast-derived using animal-free media, targeting applications in bioscience, cosmetics, functional foods, and pharmaceuticals. The company holds patents in USA, Canada, China, and EU for its methanol-free fermentation process.

Differentiator

Problem solved

Functional benefit

Products and services

• Human Epidermal Growth Factor (hEGF) A small, potent growth factor encoded by the HOMG4 (URG) gene that induces proliferation, differentiation, and survival of numerous cell types. Sold by Bioboost as a yeast-derived Research Use Only (RUO) protein for bioscience and cosmetic research customers.
• Recombinant Human Serum Albumin (rHSA) A yeast-derived recombinant form of human serum albumin (~66.5 kDa, 585 amino acid residues) produced by Bioboost for use as a stabilizing agent in vaccines, drug delivery systems, and as an intravenous therapeutic agent for hypoalbuminemia. Sold as an RUO reagent to research customers.
• Recombinant Brazzein (protein sweetener) A small, heat-stable protein sweetener derived from the African plant Pentadiplandra brazzeana (gene aliases DEF_PENBA, accession P56552). Expressed in yeast using animal-free media and offered by Bioboost as an RUO ingredient for functional food and beverage research customers.
• Methanol-Free Pichia Biosynthesis Platform Bioboost's proprietary Pichia pastoris precision fermentation platform that eliminates toxic, flammable, and explosive methanol feedstock while delivering higher production yields, enhanced secretion for lower downstream processing costs, and chaperone-enabled folding of complex proteins. Offered to enterprise partners for joint research, scale-up, and commercial supply of recombinant proteins.
• Synthetic Biology Consulting and Research Collaboration Services Paid advisory and research services including strategy, market analysis, due diligence, funding and partnership support, lab setup and operations consulting, regulatory compliance advisory, and milestone-based research and technology collaborations (e.g., the 18-month, ~$580,000 CAD Pinnacle Food Group engagement). Targets biotech, agtech, food tech, and functional food customers.

Quantifiable outcome

• Eliminates use of toxic, explosive, and flammable methanol solvent from Pichia fermentation process
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Open Yeast CollectioncoreStrategic or Co-development Partner · 20 April 2026Non-binding MOU signed to explore establishing an Open Yeast Platform hub at the Hong Kong-Shenzhen Innovation and Technology Park. The platform would distribute open-source yeast DNA parts and yeast strains to researchers worldwide under an OpenMTA framework. Bioboost provides strategic consulting and technical integration expertise.
• Pinnacle Food Group LimitedcoreStrategic or Co-development Partner · 20 January 202618-month research and technology collaboration focused on biotechnology and precision fermentation research, including recombinant human lactoferrin (rhLF) for health, nutrition, and functional food development. Includes technical consulting, ecosystem scouting, and strategic evaluations across agtech, food tech, and biotechnology. Milestone-based payments totaling approximately $580,000 CAD.
• Pinnacle Food Group LimitedminorImplementation/ SI/ Consulting Partner · 24 November 2025Bioboost providing advisory services for the setup and operation of a bioengineering and testing laboratory in Vancouver, supporting Pinnacle's smart agriculture platform. Includes advisory on regulatory compliance and operations.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bota Bio: Synthetic biology company using engineered microorganisms including yeast for sustainable production of ingredients. Comparable because it combines a synbio chassis-engineering platform with commercial ingredient production, mirroring Bioboost's dual platform + product approach.
• Perfect Day: Precision fermentation company producing animal-free dairy proteins (e.g., whey, casein) using engineered microorganisms. Comparable because it shares the precision-fermentation-to-functional-food thesis and operates in the same recombinant protein end-markets Bioboost is targeting with rhLF.
• Culture Biosciences: CDMO offering fermentation process development and manufacturing services using microbial hosts including yeast. Comparable because it serves the same biotech customer segment with process development and pilot-scale fermentation services that overlap Bioboost's consulting and research collaboration offering.
• Conagen: US-based precision fermentation company producing recombinant proteins, peptides, and specialty ingredients via engineered microbial hosts. Comparable because it operates a similar B2B services + ingredients model and shares functional food, cosmetic, and pharma end-customers.
• Biomill: French synthetic biology CRO offering yeast strain engineering and protein expression services using Pichia and other hosts. Comparable because it offers contract Pichia-based protein production and strain development directly overlapping Bioboost's core service offering.
• Codexis: US-listed protein engineering company applying directed evolution to enzymes and biotherapeutics manufacturing. Comparable because it operates at the intersection of engineered proteins and biomanufacturing process optimization, an adjacent capability to Bioboost's host engineering.
• Willow Biosciences: Canadian-listed company using Pichia pastoris for precision fermentation of ingredients, including cannabinoids and other high-value bioactives. Directly comparable because it shares the same host organism and target end-markets; Bioboost's advisor Mathias Schuetz was formerly VP R&D at Willow.

Broad incumbents

• Ginkgo Bioworks: Large US-listed synthetic biology platform serving multiple end-markets through cell engineering and fermentation services. Comparable as a broader incumbent in synbio services and ingredient production, though much larger in scale and scope than Bioboost's niche yeast platform.
• Novonesis: Global industrial biotechnology leader (formed from Novozymes and Chr. Hansen) producing enzymes, microbes, and fermented ingredients for food, health, and industry. Comparable as an incumbent operating in Bioboost's same fermentation-based end-markets at much larger scale.
• Amyris: Synthetic biology company historically focused on precision-fermented ingredients for flavors, fragrances, and health. Comparable as a pioneering player in the same fermentation-to-ingredient business model, despite its recent restructuring challenges.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bbsci

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioboost Synbio